APPLICATION OF IMMUNOMODULATING DRUG GAMAVIT IN RABBIT BREEDING AND ITS INFLUENCE ON MEAT QUALITY INDICATORS

В статье приведен анализ влияния препарата «Гамавит» на показатели качества и безопасности мяса кроликов. Гамавит – комплексный препарат, основными действующими веществами которого являются: нуклеинат натрия – 0,02мг и кислотный гидролизат плаценты денатурированной эмульгированной (ПДЭ) – 0,50мг. Экспериментальные исследования проведены на кафедре паразитологии и ветеринарно-санитарной экспертизы ФГБОУ ВО МГАВМиБ – МВА имени К.И. Скрябина. Объекты исследования – кролики породы Советская шиншилла, подобранные по принципу аналогов с учетом массы, возраста, состояния здоровья и пола, содержащиеся в одинаковых условиях на базе НИЦ эпидемиологии и микробиологии имени Н.Ф. Гамалеи, в минифермах типа кварт. Для эксперимента отобрано 20 кроликов, из которых сформировали 2 группы по 10 животных в каждой. Продолжительность опытов составляла 123 суток (подготовительный – 15 суток и учетный – 108 суток). Кролики первой, опытной группы, в составе основного рациона получали комбинированный иммуномодулирующий лекарственный препарат «Гамавит» в количестве 0,1мг/кг массы тела животного 1 раз в сутки с начала периода откорма в 1-й, 4-й и 9-й дни с интервалом в 21 день перорально. Кроликам второй, контрольной, группы препарат добавлен не был. Продукты убоя (тушка, внутренние органы) оценивались в соответствии с требованиями нормативной документации. Оценка производилась: по органолептическим показателям; была произведена товароведческая оценка туш; установлены физико-химические показатели мяса; токсичность, биологическая ценность мяса, а также качественные показатели мяса. По результатам проведенных органолептических и физико-химических исследований отрицательного влияния препарата Гамавит на качество получаемой продукции кроликов не установлено The article presents an analysis of the effect of the drug "Gamavit" on the quality and safety of rabbit meat. Gamavit is a complex preparation, the main active substances of which are: sodium nucleinate-0.02 mg and acid hydrolysate of the denatured emulsified placenta (PDE)- 0.50 mg.Experimental studies were conducted at the Department of Parasitology and veterinary and sanitary examination of the Moscow state medical UNIVERSITY named after K. I. Scriabin. The objects of research-rabbits of the breed: Soviet chinchilla, selected on the principle of analogues taking into account the weight, age, health and gender, contained in the same conditions on the basis of the SIC epidemiology and Microbiology named after N. F. Gamalei, in miniferms type quarts. For the experiment, 20 rabbits were selected, of which 2 groups were formed. The duration of the experiments was 123 days (preparatory – 15 days and accounting-108 days). The drug was not added to rabbits of the second group. Rabbits of the first, experimental group, as part of the main diet received a combined immunomodulating drug "Gamavit" in the amount of 0.1 mg \ kg of animal body weight 1 time per day from the beginning of the fattening period on the 1st, 4th and 9th day with an interval of 21 days orally. Slaughter products (carcass, internal organs) were evaluated in accordance with the requirements of regulatory documentation. The assessment was carried out according to: organoleptic indicators, commodity evaluation of carcasses was made, physical and chemical indicators of meat, toxicity, biological value of meat, as well as quality indicators of meat were established. According to the results of organoleptic and physico-chemical studies, the negative effect of the drug Gamavit on the quality of the resulting products of rabbits has not been established

Development and Validation of UV Spectroscopic Method for Estimation of Baricitinib

A simple, sensitive and reproducible spectrophotometric method for the analysis of Baricitinib in pure form and in its dosage form has been developed. Baricitinib is a synthetic antineoplastic and immunomodulating drug. Baricitinib is a selective and reversible Janus kinase 1 (JAK1) and 2 (JAK2) inhibitor. Janus kinases belong to the tyrosine protein kinase family and play an important role in the proinflammatory pathway signalling that is frequently over-activated in autoimmune disorders such as rheumatoid arthritis. Developed method obeyed beer’s law in a concentration range of 10-60 µg/ml with a correlation coefficient (R2) of 0.993. Quantification was carried out at 250 nm. Percentage assay of Baricitinib was found to be close to 100 %. The results of analysis have been validated statistically and recovery studies confirmed the accuracy of the proposed method.

Antitumoral drug loaded in TEOS nanoparticles

ABSTRACTMethotrexate (MTX), is a potent immunomodulating drug and widely used in the treatment of cancer, psoriasis and others disease. Despite its efficacy, the use of MTX is greatly limited due to its toxicity. To solve this problem, we prepared nanoparticles of tetraethyl orthosilicate (NP-TEOS) containing the compound methotrexate (MTX), by the sol-gel method. This drug delivery system (DDS) showed a loading efficiency of 39.7%. Size distribution studies were performed with dynamic light scattering and scanning electron microscopy revealing that these particles were spherical in shape, with a mean diameter between 140-430 nm and a low polydispersity (0.12 – 0.26). Also the particles displayed a low tendency toward aggregation which was confirmed by the low zeta potential -61.4 mV. Profile release showed a slow release loaded with MTX (PBS buffer pH = 7.4). The slow release can be attributed to the low porosity of the NP-TEOS and the extremely low diffusivity of MTX in aqueous media. B16-F10 cells were used to assay the toxicity and uptake of NP-TEOS showing to be nontoxic without MTX making a good candidate for DDS.

Immunomodulating Drugs in Myelodysplastic Syndromes

Based on immune mechanisms that appear to play an important role in the pathophysiology of at least part of the lower-risk myelodysplastic syndrome (MDS), the immunomodulating drug (IMID) thalidomide and its derivative lenalidomide (LEN) have been used in MDS, principally in lower-risk MDS. LEN has become the first-line US Food and Drug Administration (FDA)–approved treatment for lower-risk MDS with 5q deletion (del5q), in which its main mechanism of action is probably a direct cytotoxic activity on the del5q clone. This possibly specific effect is currently being investigated in higher-risk MDS—and even acute myeloid leukemia (AML)—with del5q, but LEN has also demonstrated some efficacy in MDS and AML without del5q. Thalidomide also has some activity in lower-risk MDS without del5q, but its side effects limit its practical use in these patients.